nieuws Novacyt

105 Posts, Pagina: « 1 2 3 4 5 6 » | Laatste
voda
0
29/09/20 Posted in Board, Novacyt Group, Products, Uncategorized

Launch of COVID-19 antibody test

Paris, France and Camberley, UK – 29 September 2020 – Novacyt, an international specialist in clinical diagnostics, announces that, further to the announcement on 27 July 2020, the Company has launched a CE-Mark approved serology (antibody) 96-well plate ELISA (enzyme-linked immunosorbent assay) test for the detection of IgG antibodies to SARS-CoV-2 derived from plasma and serum samples.

novacyt.com/wp-content/uploads/2020/0...
voda
0
29/09/20 Posted in Board, Novacyt Group, Products, Uncategorized

New contract with UK DHSC for instrument platforms and COVID-19 testing kits

Paris, France and Camberley, UK – 29 September 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a new supply contract with the UK Department of Health and Social Care (DHSC) for its q16 and q32 Rapid-PCR instrument platforms, exsig® COVID-19 Direct kits and genesig® SARS-CoV-2 Winterplex kits.

novacyt.com/wp-content/uploads/2020/0...
voda
0
NOVACYT
Limited company with registered capital of 4,708,416.54 euros
Registered office: 13 avenue Morane Saulnier – 78140 Vélizy-Villacoublay
491 062 527 Versailles Trade and Companies Register

Text of Resolutions

novacyt.com/wp-content/uploads/2020/0...
voda
0
Novacyt S.A. - Result of AGM
29th September 2020, 18:00

Novacyt S.A.

("Novacyt" or the "Company")

RESULTS OF ANNUAL GENERAL MEETING

Paris, France and Camberley, UK - 29 September 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that its Annual General Meeting (AGM), including its ordinary and extraordinary general meetings, was held this afternoon.

The Company is pleased to report that both meetings were quorate and that all resolutions proposed to the shareholders were duly passed.

The results of the AGM voting will be available on the Company's website shortly.

www.voxmarkets.co.uk/rns/announcement...
voda
1
Met dank aan poster Cruiser2010

Voor de boekhouders onder ons van ShaunP op het Engelse forum gepubliceerd

www.docdroid.net/eVv4g0o/00-novacyt-f...

Veel feiten en andere handige informatie, grote pdf met 23 bladzijden.
voda
0
Maandelijkse informatie over het liquiditeitscontract en over het totale aantal stemrechten
02 OKT 2020 14:30 CEST

BEDRIJFSNAAM
NOVACYT

ISN
FR0010397232

MARKT
Euronext-groei

SYMBOOL
ALNOV

Parijs, Frankrijk en Camberley, Verenigd Koninkrijk - 2 oktober 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), een internationale specialist in klinische diagnostiek, publiceert maandelijks rapport over het aantal aandelen dat wordt verhandeld onder het toevertrouwde liquiditeitscontract om Securities SA te investeren (de “Liquiditeitsovereenkomst”). Het liquiditeitscontract valt onder de Franse wetgeving en wordt samengevat aan het einde van het persbericht in het deel "Aanvullende toelichtingen".

Gedurende de periode van 1 september tot 30 september 2020 kocht Invest Securities 12.516 gewone aandelen tegen een maximale prijs van 5,88 euro en een minimumprijs van 3,30 euro en verkocht 15.066 gewone aandelen tegen een maximale prijs van 6 euro. 17 euro en een minimumprijs van 3,33 euro onder het liquiditeitscontract. Het totale aantal gewone aandelen van de Vennootschap dat bij sluiting van de markt op 30 september 2020 in eigen bezit wordt gehouden, bedraagt ??7.400.

Totaal aantal stemrechten

Het totale aantal gewone aandelen in de vennootschap bedraagt 70.626.248. Dit cijfer kan door aandeelhouders worden gebruikt als noemer om te berekenen of zij hun belang in de vennootschap of een wijziging in hun belang in de vennootschap moeten bekendmaken. hier, in overeenstemming met artikel L. 223-7 van het Franse Wetboek van Koophandel en de statuten van de Vennootschap. De Vennootschap is niet onderworpen aan de openbaarmakingsrichtlijnen en transparantieregels die zijn opgesteld door de Financial Conduct Authority in Deel VI van de Financial Services and Markets Act.

Ga voor meer informatie naar www.novacyt.com of neem contact op met:

Novacyt SA

Graham Mullis, Chief Executive Officer

Anthony Dyer, Chief Financial Officer

+44 (0)1276 600081

(vertaald uit het Frans)

live.euronext.com/nl/product/equities...
voda
0
Met dank aan Accionista. Eigenlijk "verplichte" leesstof voor de Novacyt aandeelhouders of hen die in willen stappen. 29 bladzijden leesvoer, er staat werkelijk van alles wat in.
Op o.a. blz 28 zijn alle major Contracts te zien. Mooi overzicht van wat er b.v. deze week binnengekomen is (via Primerdesign)

Accionista schreef op 10 oktober 2020 15:27:
Vers van de pers:

Overzicht van ShaunP:

filebin.net/obbxid0slw185sl0/00__Nova...

Mvg,

Accionista
voda
0
Novacyt S.A.
("Novacyt", the "Company" or the "Group")

Acquisition of IT-IS International Ltd

Deal in line with strategy, secures key IP for the Company’s rapid-PCR
instruments, expands its core capabilities and product offering

Paris, France and Camberley, UK – 15 October 2020 – Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces the acquisition of the entire share capital of IT-IS International Ltd (IT-IS), a
profitable diagnostic instrument development and manufacturing company, for an initial
cash consideration of £10.1 million. IT-IS is the exclusive manufacturer of Novacyt’s q16
and q32 rapid polymerase chain reaction (PCR) instruments.

Voor meer, zie pdf (in link)

www.iex.nl/Forum/Upload/2020/12814272...

novacyt.com/2020/10/15/acquisition-of...
voda
0
Weer een stukje nieuws:

quote:

alexnr75 schreef op 18 oktober 2020 08:47:


Novacyt to launch 3rd gen testing tech.

Exciting test updates are about to hit the market from PrimerDesign and newly acquired tech inventors IT-IS

novacytinsider.com/novacyt-to-launch-...
voda
0
Interessante leesstof:

quote:

WiHe schreef op 1 november 2020 10:18:


Financiële analyse per 31/10 van ShaunP op het Britste forum NCYT:

filebin.net/yujd97baea20vdou
voda
0
Director/PDMR Shareholding
NOVACYT S.A.
Released 07:00:06 12 November 2020

RNS Number : 0564F
Novacyt S.A.
12 November 2020

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 12 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 11 November 2020, Graham Mullis, Chief Executive of the Company, acquired 60,875 ordinary shares of €1/15 each in the Company at a price of £8.17 per share. The resultant beneficial shareholding of Mr Mullis is 122,506 ordinary shares representing 0.17% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Voor meer, zie link:

www.londonstockexchange.com/news-arti...
voda
0
Die lui daar geven een GOED signaal af! Prima voor het beleggersvertrouwen in Novacyt!!

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 13 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Jean-Pierre Crinelli, a Non-Executive Director of the Company, purchased 1,541 ordinary shares of €1/15 each in the Company at a price of €9.70 per share.

Following the purchase, Mr Crinelli is interested in 30,773 ordinary shares representing 0.04% of the issued share capital. This amount includes 8,000 ordinary shares purchased by Mr Crinelli at a price of €1.274 per share on 20 March 2020 which inadvertently was not disclosed by Mr Crinelli at the time.

www.londonstockexchange.com/news-arti...
voda
0
Zijn goed bezig daar!

Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 13 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 13 November 2020, James McCarthy (PDMR), a corporate consultant, acquired 10,000 ordinary shares of €1/15 each in the Company at an average price of £8.953 per share. The resultant beneficial shareholding of Mr McCarthy is 10,000 ordinary shares representing 0.01% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

www.voxmarkets.co.uk/rns/announcement...
voda
0
Novacyt S.A.
("Novacyt", the "Company" or the “Group”)

R&D Update
Continued expansion of COVID-19 product portfolio to address unmet
market needs

Paris, France and Camberley, UK – 16 November 2020 – Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces an R&D update.

R&D highlights
• Encouraging interim data from ongoing clinical trial in care homes confirms
accuracy of Novacyt’s near-patient testing (NPT) system compared to central
laboratory testing of COVID-19
• Launch of PROmate™, a new product to improve the workflow efficiency of
Novacyt’s NPT system for COVID-19 testing
• Development of a loop-mediated isothermal amplification (LAMP) test for COVID19
• Development of an antibody lateral flow test (LFT) for COVID-19
• Development of a research-use-only (RUO) test for a new strain of COVID-19

Novacyt's near-term focus remains to deliver strong organic revenue growth in the core
business, where the Directors believe demand for its products will continue to grow well
into 2021 as COVID-19 testing continues. In the medium-term, Novacyt expects to
leverage its reputation, market intelligence and relationships developed during the COVID19 response to commercialise new products, as well as expand its presence in respiratory
and transplant clinical diagnostics, to continue to meet significant unmet market needs.
As part of Novacyt’s strategy, the Company also continues to invest in developing its IP
portfolio to enhance and secure future value and has submitted 15 new patents covering
various aspects of its COVID-19 portfolio.

Clinical trial update using Novacyt’s NPT system in care homes
Further to the announcement on 22 July 2020, Queen Mary University of London (QMUL)
has completed an interim review of the performance of the Company’s innovative nearpatient testing (NPT) system in an ongoing study testing for COVID-19 in care homes.

The interim review analysed over 4,000 samples from care home residents and staff, with
98% of the samples using Novacyt’s NPT system processed and reported in the same day.
The clinical accuracy of Novacyt’s NPT system was found to have >99% clinical sensitivity
and specificity when compared to a standard central laboratory system. These data
demonstrate the reliability and accuracy of Novacyt’s NPT system. In addition, mid-nose
nasal swabs were found to be effective and well tolerated compared to the more invasive
nasopharyngeal swabs.

Further to the announcement of Novacyt’s second contract with the UK DHSC on 29
September 2020 for the supply of q16 and q32 instruments and test kits to NHS hospitals,
the clinical trial is being expanded into additional settings across the UK where the
Company’s NPT systems are being deployed.

Launch of PROmate™
PROmate™ is a new CE Mark approved product designed to further improve the workflow
efficiency of COVID-19 testing when used in combination with the Company’s q16 and q32
instruments. The reagents involved in the Company’s COVID-19 RNA extraction and PCR
test products have been repackaged, with some reagents also freeze-dried, to reduce the
amount of consumables and the number of steps required, thereby reducing operator
complexity and improving cycle times. In addition, PROmate™ uses a viral inactivation
methodology validated by Public Health England for potential use outside of laboratory
environments.

As Novacyt’s NPT system continues to be deployed across the NHS, and globally, this
improvement in workflow efficiency for COVID-19 testing is expected to make the system
one of the quickest and easiest to use PCR platforms in its class.

Further to the announcement on 15 October 2020 when Novacyt acquired IT-IS
International, the Company has significantly increased the manufacturing capability of ITIS to manage the growing demand for its q16 and q32 instruments. From November 2020,
the Company has scaled-up manufacturing capacity for instrument production more than
five-fold, with further expansion planned, depending on continued demand.

Development of a LAMP COVID-19 test
Loop-mediated isothermal amplification (LAMP) technology is a single-tube technique for
the amplification of DNA and RNA and is considered a low-cost alternative to detect certain
diseases, including COVID-19. Isothermal amplification is carried out at a constant
temperature without the need for a thermal cycler, contrasting to PCR amplification, which
is carried out with a series of alternating temperature steps or cycles in a thermal cycler.

Novacyt is currently developing a LAMP test for COVID-19, including evaluating the tradeoff between cycle time and test performance. The Company expects to launch the product
during Q1 2021 with an expected cycle time of 20 minutes or lower. Novacyt’s LAMP
offering is designed to be compatible with its q16 and q32 instruments. The Company is
also in active discussions with several potential partners who are seeking support to
develop, manufacture and supply LAMP tests for their instrument platforms.

Development of an antibody lateral flow test for COVID-19
On 29 September 2020, Novacyt announced the launch of its IgG specific antibody test
for use in central laboratory testing. The Company is also working on developing an IgG
antibody lateral flow test (LFT) for use as a rapid antibody test for professional use. An
LFT is an easy-to-use diagnostic device used to confirm the presence or absence of a
pathogen or biomarker. The product is expected to launch during Q1 2021 and is expected
to take approximately 20 minutes or less to give a result.

Development of a RUO test for a new strain of COVID-19
Further to the identification of a mutation of COVID-19 in Danish mink, Novacyt has taken
the strategic decision to develop a research-use-only (ROU) PCR test for a specific new
strain of the virus. The analysis currently available suggests there are four mutations that
have been found in mink. One of the mutations, known as Y453F, is of potential concern
to scientists and clinicians as it causes an amino acid change which affects antibody
binding. This could have implications for vaccine strategies, which are predicated on
stimulating a defined antibody response to the virus1
.
While it is unknown what, if any, impact the amino acid modification will have on vaccines,
Novacyt believes a RUO test could help scientists and clinicians to identify patients that
carry the virus with the Y453F mutation. The Company expects to launch this novel test
in December 2020. Should a clinical need arise for the diagnostic differentiation of Y453F
1 files.ssi.dk/Mink-cluster-5-short-rep...
from other strains of COVID-19 infection, Novacyt will be well positioned to offer this as a
clinical use diagnostic product.

Graham Mullis, Group CEO of Novacyt, commented:
“Novacyt continues to innovate in its response to the rapidly changing needs of the COVID19 testing market. In particular, the launch of PROmate™ is expected to further improve
the workflow efficiency of our near-patient testing system, enabling reduced operator
complexity and faster cycle times for our market leading PCR COVID-19 test. Not only do
the additions to the portfolio broaden the Company’s ability to support clinicians and
laboratories through the pandemic, they also strengthen our position in infectious disease
diagnostics as we continue to redefine our R&D pipeline for the next three years, in line
with our long-term growth strategy.”
- End -

novacyt.com/wp-content/uploads/2020/1...
voda
0
Novacyt S.A.

("Novacyt" or the "Company")

Director/PDMR Shareholding

Paris, France and Camberley, UK - 18 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 12 November 2020, Anouska Penny-Gibson, a person closely associated (PCA) to Steve Gibson, a PDMR of Novacyt, acquired 697 ordinary shares of €1/15 each in the Company at an average price of £8.59 per share. The resultant beneficial shareholding of Mr. Gibson is 9,116 ordinary shares representing 0.01% of the Company's issued share capital.

Voor meer, zie link:

www.londonstockexchange.com/news-arti...

105 Posts, Pagina: « 1 2 3 4 5 6 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 22 jan 2021 17:36
Koers 12,640
Verschil +0,260 (+2,10%)
Hoog 12,980
Laag 12,040
Volume 1.581.282
Volume gemiddeld 2.705.197
Volume gisteren 1.083.225